1 / 7

Wimo A., Winblad B., Stöffler A., Wirth Y., and Möbius H. J.

Resource Ultilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer‘s Disease. Wimo A., Winblad B., Stöffler A., Wirth Y., and Möbius H. J. Pharmacoeconomics 2003, 21 (5): 327-340. Study Design. No. of patients N = 252 (outpatients)

tivona
Download Presentation

Wimo A., Winblad B., Stöffler A., Wirth Y., and Möbius H. J.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Resource Ultilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer‘s Disease Wimo A., Winblad B., Stöffler A., Wirth Y., and Möbius H. J. Pharmacoeconomics 2003, 21 (5): 327-340

  2. Study Design No. of patients N = 252 (outpatients) Diagnosis Probable Alzheimer’s disease Design Double-blind, randomized, placebo- controlled, multicenter study Age  50 years (mean 76) Severity MMSE 3 – 14 (mean 7.9) GDS 5 – 6 FAST  6a Dose; duration 20 mg Memantine/day; 28 weeks Pharmaco- Resource Utilisation in Dementia (RUD) economic analysis Wimo et al., Pharmacoeconomics 2003

  3. Baseline Characteristics • No significant differences in demographics and the severity of the disease between treatment groups • Very high degree of mean caregiving time in this moderate to severe AD population Wimo et al., Pharmacoeconomics 2003

  4. Memantine Treatment Reduces Rate of Institutionalizations TPP, N = 166 Patient residential status at week 28 Memantine Placebo Residential status N (%) N (%) p-value Community 83 (92.2 %) 62 (81.6 %) 0.04 Institutional 7 (7.8 %) 14 (18.4%) p-value analyzed by 2 test Wimo et al., Pharmacoeconomics 2003

  5. Memantine Treatment Reduces Monthly Caregiver Resource Utilization TPP, N = 166 Mean time over 28-week study period Memantine Placebo Difference (N = 90) (N = 76) Caregiver time 413.46 455.64 52*(hours) [SD] [234.27] [232.70] Work loss 9.81 14.05 4.24(hours) [SD] [29.60] [38.72] *corrected for baseline characteristics (ANCOVA model) Wimo et al., Pharmacoeconomics 2003

  6. 8400 8000 7600 7200 6800 6400 6000 ** * Memantine Placebo Memantine Placebo Total caregiver costs Total societal costs Significant Reduction of Costs through Memantine Treatment TPP, N = 166 Adjusted mean monthly costs US Dollars / month * p < 0.03, ** p < 0.01 versus placebo Wimo et al., Pharmacoeconomics 2003

  7. Summary • Caregiver time and institutionalization were the main cost drivers • Average monthly caregiver costs were $ 824 lower in the memantine group* • Average monthly societal costs were $ 1090 lower in the memantine group* • Conclusion:Memantine treatment may lead to significant cost savings by reduction of resource utilization * corrected for confounding effects Wimo et al., Pharmacoeconomics 2003

More Related